249 related articles for article (PubMed ID: 30896884)
1. Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Xiao Z; He Y; Liu C; Xiang L; Yi J; Wang M; Shen T; Shen L; Xue Y; Shi H; Liu P
Oncol Rep; 2019 May; 41(5):2667-2678. PubMed ID: 30896884
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
3. KDM6B promotes ESCC cell proliferation and metastasis by facilitating C/EBPβ transcription.
Qin M; Han F; Wu J; Gao FX; Li Y; Yan DX; He XM; Long Y; Tang XP; Ren DL; Gao Y; Dai TY
BMC Cancer; 2021 May; 21(1):559. PubMed ID: 34001062
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma.
Hashizume R; Andor N; Ihara Y; Lerner R; Gan H; Chen X; Fang D; Huang X; Tom MW; Ngo V; Solomon D; Mueller S; Paris PL; Zhang Z; Petritsch C; Gupta N; Waldman TA; James CD
Nat Med; 2014 Dec; 20(12):1394-6. PubMed ID: 25401693
[TBL] [Abstract][Full Text] [Related]
5. Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Wang HL; Liu MM; Ma X; Fang L; Zhang ZF; Song TF; Gao JY; Kuang Y; Jiang J; Li L; Wang YY; Li PL
Asian Pac J Cancer Prev; 2014; 15(7):3051-6. PubMed ID: 24815446
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
7. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
[TBL] [Abstract][Full Text] [Related]
8. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
[TBL] [Abstract][Full Text] [Related]
9. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
Sarfstein R; Friedman Y; Attias-Geva Z; Fishman A; Bruchim I; Werner H
PLoS One; 2013; 8(4):e61537. PubMed ID: 23620761
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
[TBL] [Abstract][Full Text] [Related]
11. KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma.
Jiang Y; Li F; Gao B; Ma M; Chen M; Wu Y; Zhang W; Sun Y; Liu S; Shen H
Theranostics; 2021; 11(8):3868-3881. PubMed ID: 33664867
[No Abstract] [Full Text] [Related]
12. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.
Theisen ER; Gajiwala S; Bearss J; Sorna V; Sharma S; Janat-Amsbury M
BMC Cancer; 2014 Oct; 14():752. PubMed ID: 25300887
[TBL] [Abstract][Full Text] [Related]
13. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372
[TBL] [Abstract][Full Text] [Related]
14. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas.
Semczuk A; Boltze C; Marzec B; Szczygielska A; Roessner A; Schneider-Stock R
J Cancer Res Clin Oncol; 2003 Oct; 129(10):589-96. PubMed ID: 12920579
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.
McLaughlin-Drubin ME; Park D; Munger K
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16175-80. PubMed ID: 24046371
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.
Yang T; Qiu H; Bao W; Li B; Lu C; Du G; Luo X; Wang L; Wan X
PLoS One; 2013; 8(6):e67458. PubMed ID: 23840707
[TBL] [Abstract][Full Text] [Related]
18. Histone demethylase KDM6B regulates 1,25-dihydroxyvitamin D3-induced senescence in glioma cells.
Sui A; Xu Y; Pan B; Guo T; Wu J; Shen Y; Yang J; Guo X
J Cell Physiol; 2019 Aug; 234(10):17990-17998. PubMed ID: 30825201
[TBL] [Abstract][Full Text] [Related]
19. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
Qiu MT; Fan Q; Zhu Z; Kwan SY; Chen L; Chen JH; Ying ZL; Zhou Y; Gu W; Wang LH; Cheng WW; Zeng J; Wan XP; Mok SC; Wong KK; Bao W
Oncotarget; 2015 Oct; 6(31):31702-20. PubMed ID: 26397136
[TBL] [Abstract][Full Text] [Related]
20. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
